| 435 | 52 | 32 |
| 下载次数 | 被引频次 | 阅读次数 |
目的:观察瓜蒌薤白半夏汤合丹参饮治疗不稳定型心绞痛(UA)痰瘀互结证的临床疗效及安全性。方法:研究纳入80例低、中危的UA属痰瘀互结证的患者,随机分成试验组与对照组各40例。对照组给予西医常规治疗,试验组给予西医常规加中药颗粒瓜蒌薤白半夏汤合丹参饮治疗,干预4周,观察记录干预前后两组患者心绞痛的发作情况、中医证候积分、硝酸甘油使用量、生活质量评分、血脂、凝血指标以及临床总疗效。结果:治疗4周后,两组心绞痛的发作情况(发作次数、持续时间)均较前改善,且试验组比对照组效果更佳,差异具有统计学意义(P<0.05);试验组硝酸甘油停减率优于对照组,差异具有统计学意义(P<0.05);两组的临床总有效率比较,差异具有统计学意义(P<0.05);试验组的中医证候积分明显低于对照组,差异具有统计意义(P<0.05);试验组的血脂指标低密度脂蛋白(LDL-C)、总胆固醇(TC)及凝血指标凝血酶原时间(PT),改善程度均优于对照组,差异具有统计学意义(P<0.05)。研究期间,两组均未发生明显的不良反应。结论:瓜蒌薤白半夏汤合丹参饮能有效缓解UA痰瘀互结证患者心绞痛的发作,减少硝酸甘油的使用量,调节患者的血脂水平及血流状态,有效改善患者的临床症状,提高生活质量,药物的安全性较好。
Abstract:Objective:To observe the clinical efficacy and safety of Gualou Xiebai Banxia decoction combined with Danshen decoction on unstable angina(UA)with phlegm and blood stasis syndrome.Method:Eighty patients with UA were divided into the treatment group(40 cases)and the control group(40 cases)by random number table method. The control group was given conventional western medicine treatment,and the experimental group was given Gualou Xiebai Banxia decoction and Danshen decoction on the basis of the western medicine treatment. Both groups were treated for 4 weeks. Before and after treatment,the angina attacks,dosage of nitroglycerin,traditional Chinese medicine syndrome score,quality of life score,blood lipid,coagulation index and clinical total efficacy were observed and recorded. Results:After 4 weeks of treatment,both of the attack times and duration of angina in the two groups decreased compared with those before treatment. And the treatment group showed more reductions than the control group,the difference was statistically significant(P<0.05);the consumption of nitroglycerin of the treatment group was 90.0%,which was better than that of the control group(67.5%)with statistically significant difference(P<0.05);the total effective rate of the treatment group was 90%,which was better than that of the control group(65%)with statistically significant difference(P< 0.05);the traditional Chinese medicine(TCM)syndrome score of the experimental group was lower than that of the control group with statistically significant difference(P<0.05). The improvement of low density lipoprotein(LDL-C),total cholesterol(TC)and prothrombin time(PT)in the experimental group was better than that in the control group(P<0.05). During the study,there were no obvious adverse reactions in both groups.Conclusion:Gualou Xiebai Banxia decoction combined with Danshen decoction can effectively relieve the attack of angina and the consumption of nitroglycerin,improve clinical symptoms. regulate blood lipid and blood flow state,and improve the quality of life of patients with UA,with good clinical efficacy and safety.
1胡盛寿,高润霖,刘力生,等.《中国心血管病报告2018》概要[J].中国循环杂志,2019,34(3):209-220.
2 Cairns JA,Fantus IG,Klassen GA.Unstable angina pectoris[J]. Ame Heart J,1987,92(3):373-386.
3 蒋跃绒,王培利,付长庚,等.冠状动脉血运重建术后心绞痛中西医结合诊疗指南[J].中国中西医结合杂志,2020,40(11):1298-1307.
4 薛梅袁,薛丽娜,史大卓.阿司匹林抵抗中西医结合防治进展与展望[J].中国中西医结合杂志,2014,34(2):245-249.
5 陈红.浅谈冠心病二级预防[J].心电与循环,2019,38(5):364-366.
6 王玉平,赵树武,金娜娜.冠脉介入术后再狭窄原因分析及对策[J].中国社区医师(医学专业),2012,14(28):38-39.
7 杜建超.基于数据挖掘的冠心病不稳定型心绞痛证素分布及用药规律研究[D].北京中医药大学,2014.
8 曹洪欣,张华敏.痰瘀互结与冠心病发病机理辨识[J].中医药学刊,2001,19(6):544-545.
9 Braunwald E,Antman EM,Beasley JW,et al.ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(Committee on the Management of Patients With Unstable Angina)[J]. J Am Coll Cardiol,2000,36(3):970-1062.
10 郑筱萸.中药新药临床研究指导原则:试行[M].北京:中国医药科技出版社,2002:68-73.
11 沈绍功,姚金城.中医心病之心绞痛诊断与疗效标准[J].中国医药学报,2004,(10):581-583.
12 虞抟.医学正传[M].北京:人民卫生出版社,1965:301.
13 葛均波,徐永健.内科学[M].8版,北京:人民卫生出版社,2013:236-242.
14 Sundb?ll J,Larsen AP,Veres K,et al. Cardiovascular event rates and trajectories of LDL-cholesterol levels and lipid-lowering therapy in patients with atherosclerotic cardiovascular disease:A population-based cohort study[J].Thromb Res,2019,183:124-130.
15 韩慧萍.老年血液高凝状态与冠心病的相关性分析[D].吉林大学,2015.
16 周明权.冠心病患者凝血四项及纤维蛋白原多态性分析[J].中国实用医药,2012,7(5):70-71.
17 张悦晨,谭舒,朱文艳,等.瓜蒌在心血管疾病应用的研究进展[J].世界最新医学信息文摘,2019,19(52):47-48.
18 孔令雷,杜冠华.丹参饮的现代研究进展[J].中药药理与临床,2019,35(3):197-200.
19 陈惠,孙朦朦,安然,等.丹参饮在心血管疾病中的应用研究[J].吉林中医药,2013,33(1):27-30.
20 李航,李建锋,赵启韬.瓜蒌薤白半夏汤的心肌保护机制研究进展[J].中医药导报,2014,20(15):39-41.
21 游维丽.浅论栝楼皮、栝楼种子和栝楼根的化学成分及药理作用[J].当代医药论丛,2017,15(23):163-164.
22 乔凤仙,蔡皓,裴科,等.中药薤白的研究进展[J].世界中医药,2016,11(6):1137-1140.
23 张明发,沈雅琴.半夏及其炮制品对神经和循环系统的药理作用研究进展[J].抗感染药学,2017,14(9):1643-1648.
24 万新焕,王瑜亮,周长征,等.丹参化学成分及其药理作用研究进展[J].中草药,2020,51(3):788-798.
基本信息:
DOI:10.13210/j.cnki.jhmu.20210301.001
中图分类号:R259
引用信息:
[1]田盼盼,李军,陈恒文,等.瓜蒌薤白半夏汤合丹参饮治疗不稳定型心绞痛痰瘀互结证的临床研究[J].海南医学院学报,2021,27(14):1059-1063.DOI:10.13210/j.cnki.jhmu.20210301.001.
基金信息:
国家中医药管理局中医临床研究基地业务建设第二批科研专项课题(JDZX2015249); 国家自然科学基金资助项目(81973836)~~
2021-03-02
2021-03-02
2021-03-02